Innovative Medicines Canada responds to the Trump administration’s plan to allow the importation of prescription drugs from Canada

Posted on September 28, 2020

STATEMENT

Ottawa, September 25, 2020 – The following statement can be attributed to Declan Hamill, Vice President, Legal, Regulatory Affairs & Compliance, Innovative Medicines Canada in response to the Trump administration’s  plan to allow the importation of prescription drugs from Canada:

“Innovative Medicines Canada is concerned by this announcement because it could impact the supply of prescription medicines available to Canadians. Canada simply cannot supply medicines and vaccines to a market ten times larger than its own population without creating shortages and exposing Canadian patients to risk.

Innovative Medicines Canada will work collaboratively with the Government of Canada and other stakeholders to ensure that Canadian patients continue to have access to the medicines and vaccines that they need.”

About Innovative Medicines Canada

Innovative Medicines Canada is the national voice of Canada’s innovative pharmaceutical industry. We advocate for policies that enable the discovery, development and commercialization of innovative medicines and vaccines that improve the lives of all Canadians. We support our members’ commitment to being valued partners in the Canadian healthcare system.

– 30 –

For further information:

Samantha Thompson
Media Relations
Telephone: 613-790-4555
E-mail: sthompson@imc-mnc.ca

Leave a Reply

Your email address will not be published. Required fields are marked *